197 related articles for article (PubMed ID: 27266365)
1. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
Zhang L; Zhang R; Yang J; Wang J; Kopeček J
J Control Release; 2016 Aug; 235():306-318. PubMed ID: 27266365
[TBL] [Abstract][Full Text] [Related]
2. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
3. N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.
Searle F; Gac-Breton S; Keane R; Dimitrijevic S; Brocchini S; Sausville EA; Duncan R
Bioconjug Chem; 2001; 12(5):711-8. PubMed ID: 11562189
[TBL] [Abstract][Full Text] [Related]
4. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
Zhang R; Yang J; Sima M; Zhou Y; Kopeček J
Proc Natl Acad Sci U S A; 2014 Aug; 111(33):12181-6. PubMed ID: 25092316
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.
Borgman MP; Coleman T; Kolhatkar RB; Geyser-Stoops S; Line BR; Ghandehari H
J Control Release; 2008 Dec; 132(3):193-9. PubMed ID: 18687371
[TBL] [Abstract][Full Text] [Related]
6. Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Yang J; Zhang R; Pan H; Li Y; Fang Y; Zhang L; Kopeček J
Mol Pharm; 2017 May; 14(5):1384-1394. PubMed ID: 28094954
[TBL] [Abstract][Full Text] [Related]
7. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
8. Passive and active hepatoma tumor targeting of new N-(2-hydroxypropyl)methacrylamide copolymer conjugates: synthesis, characterization, and evaluation in vitro and in vivo.
Yuan J; Yuan B; Guo H; Zeng X; Wang X; Liao S; Li J; Jia Z; Song F; Wang F
J Biomater Sci Polym Ed; 2013; 24(12):1472-83. PubMed ID: 23829459
[TBL] [Abstract][Full Text] [Related]
9. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
10. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
[TBL] [Abstract][Full Text] [Related]
12. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
[TBL] [Abstract][Full Text] [Related]
13. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.
Buckway B; Frazier N; Gormley AJ; Ray A; Ghandehari H
Nucl Med Biol; 2014 Mar; 41(3):282-9. PubMed ID: 24461626
[TBL] [Abstract][Full Text] [Related]
14. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
Borgman MP; Aras O; Geyser-Stoops S; Sausville EA; Ghandehari H
Mol Pharm; 2009; 6(6):1836-47. PubMed ID: 19743884
[TBL] [Abstract][Full Text] [Related]
16. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI.
Wang Y; Ye F; Jeong EK; Sun Y; Parker DL; Lu ZR
Pharm Res; 2007 Jun; 24(6):1208-16. PubMed ID: 17387601
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.
Hongrapipat J; Kopecková P; Liu J; Prakongpan S; Kopecek J
Mol Pharm; 2008; 5(5):696-709. PubMed ID: 18729468
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
[TBL] [Abstract][Full Text] [Related]
20. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.
Kasuya Y; Lu ZR; Kopecková P; Tabibi SE; Kopecek J
Pharm Res; 2002 Feb; 19(2):115-23. PubMed ID: 11883637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
